Clinical Trials Browser

Phase 3 × Prostatic Neoplasms × Therapeutics × Clear all

NCT00415246 2019-11-22

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Phase 3 Terminated

Prostatic Neoplasms